Vasculitis D014657

Diseases [C] » Cardiovascular Diseases [C14] » Vascular Diseases » Vasculitis

Description

Inflammation of any one of the blood vessels, including the ARTERIES; VEINS; and rest of the vasculature system in the body.   MeSH

Hierarchy View

Subtype Terms (14)

Aortitis
 

Arteritis
44 drugs (38 approved, 6 experimental)

Behcet Syndrome
38 drugs (32 approved, 6 experimental)

Cogan Syndrome
 

Malignant Atrophic Papulosis
 

Mucocutaneous Lymph Node Syndrome
14 drugs (13 approved, 1 experimental)

Phlebitis
20 drugs (11 approved, 9 experimental)

Purpura, Schoenlein-Henoch
23 drugs (18 approved, 5 experimental)

Retinal Vasculitis
5 approved drugs

Shwartzman Phenomenon
 

Systemic Vasculitis
47 drugs (37 approved, 10 experimental)

Thromboangiitis Obliterans
4 experimental drugs

Vasculitis, Central Nervous System
41 drugs (33 approved, 8 experimental)

Vasculitis, Leukocytoclastic, Cutaneous
8 drugs (7 approved, 1 experimental)


Approved Indicated Drugs (4)


Organization Involved with Phase 3 Indications (65)

Key: D014657 (16) Subtype (49)

Organization Involved with Phase 2 Indications (60)

Key: D014657 (13) Subtype (47)

Organization Involved with Phase 1 Indications (2)

Hierarchy Tree View

UMLS Data


YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.